Datos Health raises $7m Series A financing led by Crescendo Venture Partners

– ISRAEL, Tel Aviv –  Datos Health, provider of an automated remote care platform, today announced the completion of a $7 million Series A round of financing led by Israeli venture fund Crescendo Venture Partners, alongside Industry Ventures, a leading US venture capital fund, joined by existing investors Vertex and Angular Ventures.

The investment brings Datos’ total funding to $9.2 million and will help the company expand its sales and marketing efforts, accelerate product development, increase talent acquisition and foster the company’s rapid growth.

“The coronavirus pandemic has served as an unwitting catalyst for transforming healthcare systems around the world at a remarkable pace. The demand for data-driven patient engagement and home hospitalization solutions is increasing rapidly, as hospitals seek to optimize resources and manage huge influxes of patients,” said Yuval Avni, Managing General Partner at Crescendo Venture Partners. “The Datos team has responded to the current crisis, and the impressive early market adoption of its platform has confirmed to us that its approach to patient care and data handling can significantly support the needed shift to home hospitalization.”

Datos Health provides a fully automated remote care platform that directly connects patients – from the comfort of their homes – with healthcare providers. Utilizing its robust data engine, Datos increases care teams’ patient management capacity, making it possible to safely monitor, detect, analyze and predict adverse events or other changes in patient conditions. This enables care teams to communicate and intervene in real-time to manage even the most complex medical treatment protocols.

“Both our new and existing investors have been incredibly supportive at this time, as our team works around the clock to offer healthcare provider partners the tools to quickly manage the transition of lower risk COVID-19 patients to home care environments,” said Uri Bettesh, Founder and CEO..

Bettesh added, “This investment round validates our mission to move care from the hospitals to the home and become the foundation for future bedless hospitals – the need for which has become painfully clear over the past several months. The positive feedback we’ve received from our customers demonstrates that Datos can become a crucial partner for health systems to help alleviate patient-overload on overburdened hospitals and improve the quality of care for patients who can be cared for at home.”

About Datos Health

Datos Health is a provider of a robust, hospital-grade Remote Care platform representing a groundbreaking, fully automated approach to patient care and data handling. The Datos platform is a true game-changer in that it delivers on the promise and full potential of patient-generated healthcare data, by enabling automation of patient journeys at a highly affordable cost. Datos utilizes advanced analytics and works agnostically across any treatment protocol, patient profile, data source, wearable and medical device, allowing automated detection, management and prediction of irregular symptoms. The platform enables rapid and seamless implementation of remote care within existing workflows and ultimately improves effectiveness throughout care pathways.

For more information: https://www.datos-health.com

About Crescendo Venture Partners

Crescendo Venture Partners is a Tel-Aviv based venture capital firm focusing on Israeli early-stage software companies that is seeking to join ambitious entrepreneurs who want to build sustainable and profitable businesses based on solid foundations and with the potential of becoming category leaders of the future.

For more information https://cr-vp.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.